FDA
FDA biologics chief Vinay Prasad to leave agency at end of April
An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya
Dr. Vinay Prasad, who leads the FDA division that oversees vaccines and other biological products, will leave the agency at the end of April, FDA Commissioner Marty Makary told staff in an email. It will be Prasad’s second departure in less than a year after a brief exit last summer amid clashes over high-profile drug and vaccine reviews.
The FDA has cleared Dexcom’s Stelo Glucose Biosensor System for use by people ages 2 and older who do not use insulin. The decision, announced June 12, makes Stelo the first over-the-counter continuous glucose monitor approved for children.
An Ruwaito ta hanyar AI
The U.S. FDA has approved Afrezza for children and adolescents with diabetes ages 6 and older. MannKind Corporation held a conference call on May 29, 2026, to discuss the decision.
A federal judge in Texas has issued a ruling limiting the FDA's approval of mifepristone, the primary drug used in medication abortions. The decision revives a long-standing lawsuit challenging the drug's safety and regulatory process. This comes amid ongoing legal battles over abortion access following the Supreme Court's overturning of Roe v. Wade.
An Ruwaito ta hanyar AI
Republican Senator Josh Hawley from Missouri has sharply criticized the Food and Drug Administration for approving a new abortion drug, raising concerns about women's safety and the agency's trustworthiness. In a letter to FDA Commissioner Robert Califf, Hawley accused the agency of prioritizing politics over science. The move highlights ongoing debates over abortion access and regulatory oversight.
The U.S. Food and Drug Administration has granted accelerated approval to Forzinity, the first treatment for Barth syndrome, a rare X-linked genetic disorder primarily affecting males. Developed by Stealth Biotherapeutics, the therapy targets mitochondrial dysfunction underlying the condition, offering new hope for patients with this life-threatening disease. This milestone follows years of advocacy and highlights progress in addressing ultra-rare disorders.
An Ruwaito ta hanyar AI
The U.S. Food and Drug Administration has approved a new device for detecting hypertension, integrating advanced sensor technology. This innovation aims to improve early diagnosis and management of the condition.
Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status
April 30, 2026 05:54Syntara reports positive FDA feedback on amsulostat trial
April 13, 2026 22:13FDA approves Travere Therapeutics' FILSPARI for FSGS
January 01, 2026 08:26US FDA approves first oral pill for thalassaemia anaemia
November 20, 2025 04:09Paradromics receives FDA approval for brain implant trial
October 02, 2025 00:19Senate confirms Robert Califf as FDA commissioner
September 30, 2025 00:32Supreme Court upholds FDA approval of mifepristone
September 30, 2025 00:32FDA issues final rule on clinical trials diversity
September 26, 2025 00:23Coalition Opposes FDA's Proposed Ban on 7-OH Substance
September 22, 2025 00:09FDA Approves Injectable Form of Merck's Keytruda